Celldex Therapeutics reported $87.27M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Agenus USD 19.81M 293.94M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Celldex Therapeutics USD 87.27M 511.09M Dec/2025
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025